ANSWER: A

Rationale:

This question asked you to apply the 2017 ACC/AHA classification thresholds. Stage 1 hypertension is defined as systolic BP 130–139 mmHg OR diastolic BP 80–89 mmHg.

• Option A: Option A meets this definition — systolic 132 mmHg falls within the 130–139 mmHg range, and the diastolic of 78 mmHg does not need to meet any additional threshold since the criteria are OR-linked.
• Option B: Option B (118/76) falls in the normal range, with systolic below 120 and diastolic below 80 — no intervention is indicated at these values.
• Option C: Option C (126/74) meets the ACC/AHA definition of elevated blood pressure — systolic 120–129 with diastolic below 80 — a real category carrying meaningful cardiovascular risk, but not yet Stage 1.
• Option D: Option D (112/68) is clearly normal on both parameters.
• Option E: Option E (144/92) actually meets the criteria for Stage 2 hypertension — systolic ≥ 140 mmHg OR diastolic ≥ 90 mmHg — which is the category above Stage 1, making it an incorrect answer to this question about Stage 1 thresholds.

ANSWER: B

Rationale:

This question asked you to recall the fundamental hemodynamic equation governing blood pressure. BP = CO × total peripheral resistance (TPR) (cardiac output times total peripheral resistance) is the foundational equation from which all antihypertensive pharmacology flows — every drug class ultimately works by reducing one or both of these variables. Option D uses physiologically real terms (preload and afterload) but incorrectly combines them as a product yielding BP — preload and afterload influence CO and resistance respectively but are not directly multiplied to give BP.

• Option A: Option A is incorrect because stroke volume alone does not determine cardiac output (heart rate also contributes), and the resistance term must be total peripheral resistance as the product variable in the BP equation.
• Option C: Option C describes the determinants of cardiac output itself (CO = HR × SV), not blood pressure — this is a useful relationship but is not the BP equation.
• Option E: Option E inverts the relationship — mean arterial pressure (MAP) and pulse pressure are derived from blood pressure, not the other way around.

ANSWER: B

Rationale:

This question asked you to recall the epidemiological breakdown of hypertension by etiology and its clinical implication.

• Option B: Option B is correct: primary (essential) hypertension accounts for approximately 90–95% of all hypertension cases. The remaining 5–10% are secondary causes — forms of hypertension with an identifiable, often treatable underlying etiology. This fraction is clinically important because secondary causes are frequently underdiagnosed, and when identified and treated etiologically, hypertension can be cured or substantially reduced without lifelong antihypertensive therapy. Renal parenchymal disease is the most common secondary cause overall; primary aldosteronism is the most common endocrine secondary cause.
• Option A: Option A (50–60%) dramatically underestimates primary hypertension and overstates secondary causes to a degree that would fundamentally alter clinical screening practice.
• Option C: Option C (70–75%) also substantially underestimates the primary fraction.
• Option D: Option D (80–85%) is closer but still underestimates the correct 90–95% figure.
• Option E: Option E (99%) dramatically underestimates secondary hypertension and incorrectly implies it does not warrant clinical attention — a patient with a curable secondary cause who is instead managed indefinitely on antihypertensives has been significantly undertreated.

ANSWER: A

Rationale:

This question asked you to correctly sequence the RAAS cascade. Option A is correct: reduced renal perfusion pressure stimulates juxtaglomerular cells to release renin, which cleaves hepatic angiotensinogen into the inactive decapeptide angiotensin I; ACE on pulmonary vascular endothelium converts Ang I to the active Ang II; Ang II stimulates adrenal aldosterone secretion; aldosterone acts on mineralocorticoid receptors in the collecting duct to promote sodium reabsorption and potassium excretion.

• Option B: Option B incorrectly places ACE activation before renin and reverses the sequence — ACE acts after renin, not before, and aldosterone release follows Ang II generation, not ACE activation directly.
• Option C: Option C incorrectly states that angiotensin I is released from the adrenal cortex (it is produced by renin's action on hepatic angiotensinogen) and that renin cleaves Ang I to Ang II (that is ACE's function); it also incorrectly states aldosterone causes potassium retention when in fact aldosterone causes potassium excretion.
• Option D: Option D incorrectly states Ang II originates from the liver and that renin activates aldosterone directly, bypassing the ACE step; it also incorrectly states sodium excretion as the final renal effect.
• Option E: Option E reverses the roles of renin and ACE entirely and incorrectly states that aldosterone promotes potassium retention.

ANSWER: C

Rationale:

This question asked you to identify aldosterone's primary mechanism of blood pressure elevation. Option C is correct: aldosterone binds mineralocorticoid receptors in the principal cells of the renal collecting duct, increasing expression of epithelial sodium channels (ENaC) on the luminal membrane and Na+/K+-ATPase on the basolateral membrane. The net result is sodium reabsorption (driving obligate water retention and intravascular volume expansion) and potassium excretion — explaining the hypokalemia that is the hallmark biochemical clue of aldosterone excess states such as primary aldosteronism.

• Option A: Option A is incorrect — aldosterone does not act acutely on vascular smooth muscle as a vasoconstrictor in the direct manner described; its hemodynamic effects are volume-mediated and develop over hours to days.
• Option B: Option B is incorrect — aldosterone does not stimulate adrenal epinephrine secretion; the adrenal cortex and medulla are separate compartments with distinct regulatory mechanisms.
• Option D: Option D is incorrect — aldosterone does not directly sensitize baroreceptors; baroreceptor resetting in chronic hypertension occurs through separate mechanisms.
• Option E: Option E is incorrect — hepatic angiotensinogen synthesis is regulated by Ang II itself (via positive feedback), inflammatory signals, and estrogens; this is not aldosterone's mechanism of action.

ANSWER: A

Rationale:

This question asked you to describe the age-related hemodynamic evolution of primary hypertension. Option A is correct: in younger individuals with early-onset hypertension, elevated cardiac output driven by SNS overactivation is the predominant mechanism. Hyperadrenergic states — characterized by increased heart rate, increased contractility, and increased renin secretion — are typical of this early phase. Over time, the hemodynamic profile shifts toward increased total peripheral resistance as the predominant driver, due to structural changes in resistance arterioles (medial hypertrophy, reduced lumen diameter) that permanently raise vascular resistance even if sympathetic tone normalizes. Understanding this shift has direct pharmacological implications: drugs that reduce CO (beta-blockers) may be relatively more effective early, while drugs targeting TPR (vasodilators, ACE inhibitors, CCBs) may be more effective in established hypertension.

• Option B: Option B incorrectly identifies primary volume overload as the early mechanism of primary hypertension; while sodium retention contributes, the dominant early mechanism is hyperadrenergic.
• Option C: Option C incorrectly places increased peripheral resistance in the early phase and inverts the progression — arterial wall thickening is a consequence of established hypertension, not its initial cause in young patients.
• Option D: Option D incorrectly conflates primary aldosteronism with primary hypertension — these are distinct entities.
• Option E: Option E incorrectly states increased pulse wave velocity predominates in younger patients; arterial stiffness is a feature of aging and established disease, not early-onset hypertension in young individuals.

ANSWER: D

Rationale:

This question asked you to distinguish the most common secondary cause overall from the most common endocrine secondary cause — a clinically important distinction. Option D is correct: renal parenchymal disease (CKD, glomerulonephritis, polycystic kidney disease) is the most common secondary cause of hypertension overall. The mechanisms include sodium retention from reduced nephron mass, RAAS activation due to decreased renal perfusion, and reduced renal prostaglandin synthesis. Primary aldosteronism — autonomous adrenal aldosterone secretion — is the most common endocrine secondary cause, estimated at 5–10% of all hypertensive patients and a higher proportion of those with resistant hypertension.

• Option A: Option A incorrectly elevates primary aldosteronism to the most common overall secondary cause; it is most common among endocrine causes, not among all secondary causes.
• Option B: Option B incorrectly identifies renovascular hypertension as the most common overall cause — it is an important secondary cause but less prevalent than renal parenchymal disease — and incorrectly names pheochromocytoma as the most common endocrine cause; pheochromocytoma accounts for less than 1% of all hypertension.
• Option C: Option C overstates obstructive sleep apnea (OSA) as the most common secondary cause (OSA is a major contributor to resistant hypertension but is debated as a primary cause), and incorrectly names Cushing syndrome as the most common endocrine cause.
• Option E: Option E is incorrect — thyroid disease can cause hypertension but is not the most prevalent secondary cause in either category.

ANSWER: A

Rationale:

This question asked you to correctly pair Ang II receptor subtypes with their physiological consequences. Option A is correct: AT1 receptors mediate the harmful hypertensive effects of Ang II — vasoconstriction (the dominant acute pressor effect), aldosterone release from the adrenal cortex, direct renal sodium retention, sympathetic nervous system facilitation, vascular smooth muscle hypertrophy, and myocardial fibrosis. These are collectively the targets of ACE inhibitors and ARBs. AT2 receptors are generally counterregulatory — their activation produces vasodilation, natriuresis, and antiproliferative effects on vascular smooth muscle. Option C also inverts the assignment — AT1 activation produces vasoconstriction, not vasodilation.

• Option B: Option B inverts the receptor-effect pairing entirely — it assigns vasodilation to AT1 and vasoconstriction to AT2, which is pharmacologically backward and would predict that ACE inhibitors cause vasoconstriction (they do not).
• Option D: Option D inverts the receptor labels — the harmful hypertensive effects listed belong to AT1, not AT2, receptor activation.
• Option E: Option E is incorrect — AT1 and AT2 receptors have distinct and opposing effects; AT2 is not the dominant cardiovascular receptor in adults (AT1 predominates) and AT2 does not mediate vasoconstriction or aldosterone release.

ANSWER: D

Rationale:

This question asked you to define ISH and identify its underlying vascular mechanism. Option D is correct on both counts: ISH is defined as systolic BP ≥ 140 mmHg with diastolic BP below 90 mmHg. The dominant mechanism in older adults is progressive loss of large artery compliance — the aorta and major conduit vessels stiffen due to elastin degradation, collagen cross-linking, and vascular calcification. Stiffer arteries transmit the pressure wave generated by ventricular ejection faster (increased pulse wave velocity), causing the wave reflected from peripheral resistance sites to return to the central aorta during systole rather than diastole. This reflected wave adds to the systolic pressure peak (raising SBP) while reducing the diastolic contribution from elastic recoil (leaving DBP stable or falling). The result is widened pulse pressure and ISH — the dominant hypertension phenotype over age 60. Option A uses an incorrect systolic threshold of 150 mmHg rather than 140 mmHg. Option C correctly defines ISH by the BP thresholds but incorrectly attributes its mechanism to renal sodium retention — the dominant mechanism is arterial stiffness, not volume overload. Option E uses thresholds not standard to the ISH definition and incorrectly attributes ISH to aortic valve pathology.

• Option B: Option B incorrectly includes elevated diastolic pressure in the definition — ISH is specifically characterized by elevated systolic with normal or low diastolic BP.

ANSWER: D

Rationale:

This question asked you to understand the evidence basis for the 2017 guideline reclassification. Option D is correct: landmark epidemiological data demonstrated that cardiovascular risk — particularly coronary artery disease and stroke — increases continuously and log-linearly above 115/75 mmHg, with no evidence of a safe threshold below which further BP reduction ceases to be beneficial. This means individuals at 130–139/80–89 mmHg carry meaningfully elevated risk relative to those at 115/75 mmHg — the same risk-per-mmHg relationship operates across the entire range. The reclassification was intended to prompt earlier lifestyle intervention and closer clinical attention, not to mandate pharmacological treatment in all Stage 1 patients; drug therapy decisions in Stage 1 still depend on total cardiovascular risk.

• Option A: Option A is incorrect — the guideline does not recommend drug therapy for all Stage 1 patients; many are managed with lifestyle modification alone.
• Option B: Option B is incorrect — the reclassification was not based on a discrepancy between office and ambulatory BP measurement methodologies.
• Option C: Option C is incorrect — the evidence base included diverse populations, and demographic applicability was not the stated rationale for the reclassification.
• Option E: Option E is incorrect and inverts the actual finding: the JNC 7 prehypertension category was found to carry meaningful excess cardiovascular risk — that excess risk is precisely why it was reclassified upward, not because the category was risk-free.

ANSWER: C

Rationale:

This question asked you to reason through the mechanism behind inadequate diuretic response in obesity. Option C is correct: obesity drives sustained SNS activation through multiple pathways — hyperinsulinemia (insulin promotes renal sodium reabsorption directly and stimulates SNS outflow from the hypothalamus), leptin excess (leptin acts on hypothalamic neurons to increase sympathetic tone), and obstructive sleep apnea (intermittent hypoxemia causes sympathetic surges that persist into daytime). This persistent SNS activation promotes renin release, RAAS activation, and direct renal sodium reabsorption, all of which counteract the natriuretic effect of diuretics. Elevated aldosterone levels in obesity provide additional sodium-retaining pressure. Adding a RAAS inhibitor (ACE inhibitor, ARB) addresses this counter-regulatory mechanism — explaining why combination therapy is frequently required. Option A is pharmacologically implausible — adipose tissue does not enzymatically degrade diuretics.

• Option B: Option B is incorrect — there is no evidence of globally reduced tubular sodium transporter density in obesity.
• Option D: Option D is incorrect — thiazide and loop diuretics are not meaningfully metabolized by CYP3A4, and adipokines do not upregulate this enzyme pathway to a clinically relevant degree.
• Option E: Option E is incorrect — obesity increases both CO and TPR, and diuretics failing as monotherapy is the clinical observation being explained, not refuted.

ANSWER: C

Rationale:

This question asked you to identify the clinical relevance of tissue RAAS activity in the context of antihypertensive pharmacology. Option C is correct: ACE is expressed not only in pulmonary vascular endothelium (where circulating Ang II is generated) but also locally within the vasculature, myocardium, kidney, and brain. ACE inhibitors block Ang II generation at both levels; ARBs block AT1 receptors at both levels. This dual action explains the demonstrated ability of these drug classes to reduce vascular hypertrophy, myocardial fibrosis, glomerular efferent constriction, and proteinuria to a degree that goes beyond what the reduction in systemic blood pressure would predict — a critical mechanistic insight supporting their use in heart failure, CKD, post-MI remodeling, and diabetic nephropathy.

• Option A: Option A is incorrect — tissue ACE is encoded by the same gene as circulating ACE and is blocked by the same ACE inhibitors at standard doses.
• Option B: Option B is incorrect — the tissue RAAS does not require biopsy monitoring for clinical decision-making; its existence explains the drug effects observed clinically.
• Option D: Option D is incorrect — tissue RAAS signals through both AT1 and AT2 receptors; the harmful remodeling effects are primarily AT1-mediated, and ACE inhibitor use selectively reduces harmful AT1 activation.
• Option E: Option E is incorrect — tissue RAAS is tonically active in chronic hypertension and contributes continuously to structural end-organ damage.

ANSWER: B

Rationale:

This question asked you to connect AT1 receptor signaling to two distinct end-organ complications of chronic hypertension. Option B is correct: AT1 receptor activation by Ang II drives vascular smooth muscle cell hypertrophy and myocardial fibrosis through activation of growth-promoting intracellular pathways including MAP kinase and TGF-β (transforming growth factor-beta), directly explaining left ventricular hypertrophy. Simultaneously, AT1 receptors mediate preferential constriction of the glomerular efferent arteriole — increasing intraglomerular hydraulic pressure despite the upstream stenosis — and this glomerular hypertension drives protein across the filtration barrier, producing proteinuria. This mechanistic link between RAAS overactivation and both cardiac and renal end-organ damage explains why ACE inhibitors and ARBs are preferentially recommended for hypertensive patients with left ventricular hypertrophy (LVH) or proteinuria — they interrupt the underlying mechanism. Option C contains a grain of truth (aldosterone does cause myocardial fibrosis through mineralocorticoid receptor (MR)) but incorrectly excludes direct Ang II AT1 receptor signaling, which is mechanistically central to both LVH and proteinuria. Option E correctly notes the aldosterone-volume relationship but incorrectly attributes proteinuria and LVH to passive mechanical stretch from volume expansion rather than the direct growth-signaling and glomerular pressure mechanisms.

• Option A: Option A incorrectly assigns these effects to AT2 receptors, which are counterregulatory and do not drive hypertrophy or proteinuria.
• Option D: Option D incorrectly states AT1 receptors mediate afferent vasodilation — AT1 activation constricts the efferent arteriole, not the afferent.

ANSWER: A

Rationale:

This question asked you to trace the consequences of impaired endothelial NO production. Option A is correct: NO produced by endothelial nitric oxide synthase (eNOS) diffuses into adjacent vascular smooth muscle cells, where it activates soluble guanylyl cyclase to generate cyclic GMP (cGMP). cGMP activates protein kinase G, which promotes smooth muscle relaxation and vasodilation through calcium extrusion and myosin light chain phosphatase activation. When NO bioavailability is reduced — whether by superoxide-mediated scavenging of NO (forming peroxynitrite), eNOS uncoupling, or reduced substrate availability — vascular smooth muscle tone increases and peripheral resistance rises. Beyond the immediate vasoconstrictor effect, NO normally inhibits platelet aggregation, leukocyte-endothelial adhesion, and smooth muscle cell proliferation; its loss promotes the inflammatory and proliferative vascular remodeling that permanently elevates resistance and sustains hypertension structurally.

• Option B: Option B is incorrect — reduced NO does not directly activate AT1 receptors; the relationship between NO and Ang II is that Ang II generates superoxide that scavenges NO, but the direction of causation in Option B is reversed.
• Option C: Option C is incorrect — NO does not directly stimulate renin secretion from juxtaglomerular cells; renin secretion is governed by renal perfusion pressure, macula densa sodium sensing, and beta-1 adrenergic signaling.
• Option D: Option D is incorrect — NO is a modulator of arterial tone and resistance, not primarily a regulator of venous capacitance and preload.
• Option E: Option E is incorrect — reduced NO does not activate the baroreceptor reflex; baroreflex impairment in hypertension involves central resetting mechanisms distinct from NO signaling.

ANSWER: E

Rationale:

This question asked you to explain the age-related shift in hypertension phenotype. Option E is correct: large arteries (aorta, major conduit vessels) normally store systolic ejection energy elastically and release it during diastole through elastic recoil — the Windkessel effect — which maintains diastolic pressure and smooth coronary perfusion. With aging, progressive elastin degradation, collagen cross-linking, and vascular calcification stiffen these vessels. Stiffer arteries transmit pressure waves faster (increased pulse wave velocity), causing the wave reflected from peripheral resistance sites to return centrally during systole rather than diastole. This reflected wave augments the systolic pressure peak (raising SBP) while the loss of elastic recoil reduces the diastolic pressure contribution (leaving DBP stable or falling), widening pulse pressure and producing ISH.

• Option A: Option A incorrectly attributes ISH to differential RAAS effects — this mechanism would not selectively elevate systolic pressure.
• Option B: Option B incorrectly attributes ISH to selective sympathetic effects on contractility without vascular resistance changes; sympathetic changes in aging do not explain the selective systolic pattern.
• Option C: Option C describes diastolic dysfunction (a real cardiac phenomenon in aging) but conflates cardiac filling mechanics with the arterial compliance mechanism that drives ISH — diastolic dysfunction does not lower DBP in the manner described.
• Option D: Option D is incorrect — volume expansion through Frank-Starling mechanisms would raise both systolic and diastolic pressure, not selectively systolic.

ANSWER: E

Rationale:

This question asked you to interpret a specific biochemical pattern and match it to the correct secondary cause of hypertension.

• Option E: Option E is correct: the combination of hypokalemia (K+ 2.8 mEq/L), suppressed plasma renin activity, and markedly elevated aldosterone-to-renin ratio (ARR > 30 by most diagnostic protocols) is the biochemical signature of primary aldosteronism — autonomous aldosterone secretion independent of Ang II or volume status. Autonomous aldosterone suppresses renin through negative feedback on juxtaglomerular cells (the opposite of what occurs in most other secondary causes), drives potassium excretion producing hypokalemia, and causes sodium retention and refractory hypertension.
• Option A: Option A (renovascular hypertension) would present with elevated renin, not suppressed renin — reduced renal perfusion stimulates juxtaglomerular renin release.
• Option B: Option B (pheochromocytoma) would present with elevated catecholamines and episodic sympathomimetic symptoms; catecholamines stimulate renin release rather than suppress it.
• Option C: Option C (OSA with secondary aldosteronism) produces elevated rather than suppressed renin, since OSA activates the RAAS through hypoxemia-mediated SNS stimulation.
• Option D: Option D (Cushing syndrome) causes hypertension through cortisol potentiation of mineralocorticoid effects and would be accompanied by clinical features of hypercortisolism — central obesity, striae, moon facies, hyperglycemia — not the isolated biochemical pattern described.

ANSWER: E

Rationale:

This question asked you to recognize the classic presentation of a catecholamine-secreting tumor and identify the appropriate diagnostic test. Option E is correct: the classic triad of episodic headache, diaphoresis, and palpitations with paroxysmal severe hypertension is the hallmark presentation of pheochromocytoma (adrenal) or paraganglioma (extra-adrenal). Catecholamine surges from the tumor produce the episodic sympathomimetic crisis, with complete resolution between episodes because the tumor secretes intermittently. The biochemical diagnosis is made by measuring catecholamine metabolites — plasma free metanephrines (normetanephrine and metanephrine) have sensitivity exceeding 96% and are the preferred initial screening test; 24-hour urinary fractionated metanephrines are an alternative. Option C is a legitimate clinical consideration in a young woman but does not explain this classic episodic triad and is not the most likely diagnosis.

• Option A: Option A describes the appropriate workup for primary aldosteronism, which presents with sustained (not episodic) hypertension and hypokalemia with suppressed renin — not the paroxysmal triad described here.
• Option B: Option B describes initial testing for renovascular hypertension, which presents with refractory sustained hypertension, flash pulmonary edema, or ACEi-induced AKI — not episodic sympathomimetic paroxysms.
• Option D: Option D describes the initial test for Cushing syndrome, which presents with features of chronic sustained hypercortisolism rather than discrete episodic sympathomimetic paroxysms.

ANSWER: B

Rationale:

This question asked you to explain why ACE inhibitors predictably precipitate AKI in bilateral renal artery stenosis. Option B is correct: in bilateral renal artery stenosis, reduced afferent arteriolar inflow compromises the pressure driving glomerular filtration. To maintain GFR despite this, the kidney compensates through Ang II-mediated constriction of the efferent arteriole — selectively increasing intraglomerular hydraulic pressure. This compensatory efferent constriction is entirely RAAS-dependent. When an ACE inhibitor blocks Ang II generation, efferent tone is lost; intraglomerular pressure falls; GFR drops acutely and creatinine rises. This is a predictable, mechanism-based complication — not idiosyncratic toxicity — and is the reason bilateral renal artery stenosis is a contraindication to ACE inhibitor and ARB therapy.

• Option A: Option A is incorrect — ACE inhibitors do not cause direct tubular toxicity through organic anion transporter (OAT)-mediated accumulation; this mechanism does not apply to this drug class.
• Option C: Option C is incorrect — Ang I accumulation does not cause vasoconstriction; Ang I has minimal vasopressor activity compared to Ang II, and ACE blockade reduces, not increases, renal vasoconstriction overall.
• Option D: Option D is incorrect — while ACE inhibitors can cause hyperkalemia through reduced aldosterone, this does not produce acute AKI through tubuloglomerular feedback in the mechanism described here.
• Option E: Option E is incorrect — bradykinin accumulation from ACE inhibition causes vasodilation (and the dry cough side effect), not mesangial cell contraction or reduced filtration surface.

ANSWER: C

Rationale:

This question asked you to connect an elevated renin level and an imaging finding of renal artery turbulence to the correct secondary cause and its clinical recognition pattern.

• Option C: Option C is correct: elevated plasma renin activity combined with Doppler evidence of turbulent high-velocity flow in the renal artery is the diagnostic picture of renovascular hypertension. The stenotic lesion reduces renal perfusion pressure, which chronically stimulates juxtaglomerular renin secretion — hence the elevated renin (in contrast to primary aldosteronism, where autonomous aldosterone suppresses renin). Classic clinical clues prompting workup include: hypertension refractory to multiple agents, flash pulmonary edema (bilateral stenosis causing sudden volume overload), new-onset severe hypertension in a young woman (suggesting fibromuscular dysplasia) or an older atherosclerotic patient, and acute kidney injury following ACE inhibitor or ARB initiation (loss of efferent compensatory tone).
• Option A: Option A correctly identifies the renin discrepancy — primary aldosteronism is characterized by suppressed renin, not elevated, making it inconsistent with the biochemical finding presented.
• Option B: Option B correctly notes pheochromocytoma would not produce renal artery Doppler findings — catecholamine-secreting tumors are adrenal or extra-adrenal, not renal artery lesions.
• Option D: Option D (Cushing syndrome) is associated with its own clinical features and would not produce the renal artery Doppler finding described.
• Option E: Option E (OSA) contributes to resistant hypertension through neurohormonal mechanisms, not structural renal artery pathology visible on Doppler.

ANSWER: D

Rationale:

This question asked you to identify the mechanism-targeted treatment for bilateral adrenal hyperplasia causing primary aldosteronism and explain its superiority. Option D is correct: bilateral adrenal hyperplasia causes autonomous aldosterone secretion independent of Ang II. Because aldosterone secretion does not depend on RAAS activation, blocking upstream steps — whether ACE (ACE inhibitors) or renin release (beta-blockers) — does not meaningfully reduce aldosterone levels. The only pharmacologically effective approach is to block the receptor through which autonomous aldosterone exerts its renal effect: the mineralocorticoid receptor (MR) in collecting duct principal cells. Spironolactone competitively antagonizes MR and is the first-line agent; eplerenone is more MR-selective with fewer anti-androgenic side effects (less gynecomastia in men). BP control with MR antagonists in primary aldosteronism is often dramatically superior to conventional antihypertensives precisely because it addresses the etiologic mechanism rather than downstream hemodynamic consequences. Option C (thiazide diuretics) partially counteract the sodium retention but do not block the MR and cannot address the ongoing potassium wasting; they are not the mechanism-targeted therapy. Option E (CCBs) address vascular tone and are not first-line therapy directed at the aldosterone receptor mechanism.

• Option A: Option A is incorrect because autonomous aldosterone secretion is not driven by Ang II; ACE inhibition will not suppress adrenal aldosterone output.
• Option B: Option B is incorrect for the same reason — reducing renin does not suppress autonomous aldosterone secretion.

ANSWER: C

Rationale:

This question asked you to interpret hypertensive retinopathy findings and assign clinical severity. Option C is correct: flame-shaped hemorrhages occur in the nerve fiber layer of the retina and result from rupture of superficial retinal capillaries when intraretinal pressure exceeds the autoregulatory capacity of the retinal vasculature. Their presence, combined with AV nicking and focal arteriolar narrowing, places this patient in at least Grade III of the Keith-Wagener-Barker classification — indicating severe uncontrolled hypertension with autoregulatory failure and significant risk for additional end-organ damage (stroke, AKI, left ventricular decompensation). Grade IV retinopathy additionally includes papilledema, indicating hypertensive encephalopathy.

• Option A: Option A incorrectly classifies this presentation as Grade I — Grade I is characterized only by mild generalized arteriolar narrowing without hemorrhages or exudates; hemorrhages indicate a more advanced stage.
• Option B: Option B is incorrect — flame-shaped (nerve fiber layer) hemorrhages occur in hypertensive retinopathy, as well as in other conditions; they are not pathognomonic for diabetic retinopathy alone.
• Option D: Option D incorrectly assigns this presentation to Grade II — Grade II involves AV nicking and arteriolar sclerosis but does not include hemorrhages; the presence of flame-shaped hemorrhages advances the grade.
• Option E: Option E is incorrect — flame-shaped hemorrhages are never a normal variant and always indicate significant vascular pathology requiring urgent clinical attention.

ANSWER: B

Rationale:

This question asked you to reason through the mechanistic link between OSA and resistant hypertension. Option B is correct: OSA causes repetitive nocturnal hypoxemia and hypercapnia, triggering sympathetic surges with each apneic episode. Critically, these surges produce sustained daytime sympathetic hyperactivation through central sensitization of sympathoexcitatory brainstem pathways — the SNS activation does not turn off when breathing normalizes. This persistent SNS elevation drives renin release and RAAS activation, while intermittent hypoxia also directly stimulates adrenal aldosterone secretion independently of Ang II through hypoxia-inducible factor pathways. The resulting combination of high sympathetic tone, high Ang II, and high aldosterone creates a multi-pathway neurohormonal state that makes blood pressure genuinely resistant to regimens targeting only one or two of these pathways — explaining why a three-drug regimen including a diuretic may still be insufficient. continuous positive airway pressure (CPAP) therapy interrupts this cascade at its source and can produce clinically meaningful BP reductions.

• Option A: Option A is incorrect — OSA does not cause structural renal artery narrowing; the mechanism is neurohormonal, not anatomical.
• Option C: Option C is incorrect — hypoxia does not meaningfully induce CYP450 enzymes to a degree that reduces antihypertensive drug levels clinically.
• Option D: Option D is incorrect — OSA impairs baroreceptor sensitivity through resetting rather than permanent structural destruction.
• Option E: Option E overstates the hypercapnia-aldosterone link and incorrectly concludes that RAAS-targeted therapy would be ineffective; the mechanism involves RAAS activation among other pathways, and RAAS inhibition is a component of management.

ANSWER: C

Rationale:

This question asked you to evaluate the clinical relevance of the CO versus TPR distinction in antihypertensive pharmacology. Option C is correct: the distinction is clinically meaningful at multiple levels. The dominant hemodynamic mechanism shifts with age and disease stage — younger hyperadrenergic patients with elevated CO may respond better to CO-reducing agents (beta-blockers, central alpha-2 agonists), while older patients with established increased vascular resistance respond better to vasodilator drug classes (CCBs, ACE inhibitors, ARBs, thiazides). The reflex consequences also differ — pure arterial vasodilators that lower TPR without reducing HR (dihydropyridine CCBs, hydralazine) trigger reflex sympathetic activation and tachycardia, while CO-reducing drugs blunt this reflex. Comorbidity indications are tied to hemodynamic mechanisms — beta-blockers that reduce CO are preferred in heart failure with reduced EF and post-MI settings because reducing cardiac work has prognostic benefit beyond blood pressure lowering.

• Option A: Option A is incorrect — drug selection is not based solely on cost and tolerability; mechanism matching to hemodynamic profile and comorbidity is central to rational selection.
• Option B: Option B is incorrect — CO-reducing drugs are not universally superior; they have specific indications and are not preferred over TPR-reducing agents in most guidelines for uncomplicated hypertension.
• Option D: Option D is incorrect — cardiac output is absolutely modifiable pharmacologically (beta-blockers reduce it; positive inotropes increase it).
• Option E: Option E is incorrect — the CO-reducing versus TPR-reducing distinction remains clinically relevant in chronic hypertension throughout treatment, not only during acute management.